Urine Stem Cell Differentiation for Regenerative Medicine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The shortage of viable cell sources for regenerative medicine applications limits the supply of cells for tissue reconstruction and replacement, necessitating the development of alternative methods for isolating and differentiating cells for therapeutic use.
Innovation Solution
Methods for isolating and differentiating urine stem cells into various lineages, including osteogenic, chondrogenic, adipogenic, endothelial, neurogenic, and myogenic cells, using techniques such as hypoxia preconditioning and specific differentiation media, and seeding these cells onto biocompatible tissue scaffolds for tissue engineering applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional cell sources are used for regenerative medicine, then cell availability is limited, but alternative sources like urine provide abundant cell supply
Solution Approach 1:
The patent demonstrates that urine-derived stem cells possess multi-lineage differentiation capacity, enabling them to generate multiple tissue types including bone, cartilage, fat, muscle, and neural tissues. This universal differentiation capability resolves the contradiction by making a single cell source (urine stem cells) adaptable to multiple regenerative medicine applications across different tissue types.
Solution Approach 2:
The patent employs parameter changes in the form of specific differentiation media and culture conditions to direct urine stem cells toward different tissue lineages. By adjusting chemical parameters (growth factors, cytokines, medium composition) and physical parameters (oxygen tension, mechanical stimulation), the same cell source can be transformed into various tissue types, thereby resolving the versatility limitation.
2Ease of operation
If urine stem cells are used instead of traditional sources, then cell accessibility improves, but differentiation control complexity increases
Solution Approach 1:
The patent applies hypoxia preconditioning as a preliminary action before differentiation. By exposing urine stem cells to low oxygen conditions prior to differentiation induction, the cells are prepped to enhance their differentiation potential and respond more effectively to subsequent lineage-specific cues. This preliminary step simplifies the overall differentiation process by improving cell readiness.
Solution Approach 2:
The patent uses specific growth factors, cytokines, and culture media components as intermediaries to mediate the differentiation process. These intermediary substances translate the complex requirements of lineage specification into manageable chemical signals that can be controlled through medium formulation, thereby reducing the apparent complexity of the differentiation system.
3Adaptability or versatility
If multiple differentiation lineages are pursued, then tissue application versatility increases, but process time and resource requirements increase
Solution Approach 1:
The patent employs dynamic culture conditions that can be adjusted over time to optimize differentiation efficiency. By changing physical parameters (oxygen tension, mechanical loading) and chemical parameters (growth factor concentrations, medium composition) at different time points, the process accelerates differentiation while maintaining control over lineage specification, thereby reducing overall process time.
Solution Approach 2:
The patent utilizes periodic interventions such as cyclic mechanical stimulation, pulsed growth factor addition, or alternating hypoxia-reoxygenation cycles to enhance differentiation efficiency. These periodic actions stimulate cellular responses that accelerate lineage commitment and tissue formation, reducing the time required compared to static culture conditions.
Data Source
AI summary
Provided herein are stem cells and methods for producing a culture of stem cells from urine. The stem cells may be differentiated into an osteogenic, chondrogenic, adipogenic, endothelial, neurogenic or myogenic lineage. Methods of use of the cells are provided, including methods of treating a subject in need of a cell based therapy.